Dianthus Therapeutics (STU:87E) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Dianthus Therapeutics LT-Debt-to-Total-Asset?

Dianthus Therapeutics STU:87E 22 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Dianthus Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Dianthus Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.00) to Mar. 2026 (0.00). It may suggest that Dianthus Therapeutics is progressively becoming less dependent on debt to grow their business.

Dianthus Therapeutics (STU:87E) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Dianthus Therapeutics LT-Debt-to-Total-Asset Related Terms

Dianthus Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics LT-Debt-to-Total-Asset Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

0.00

0.01

0.00

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial											0.00	0.00	0.00	0.00	0.00

22GF Score

Dianthus Therapeutics Inc STU:87E

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Dianthus Therapeutics LT-Debt-to-Total-Asset Calculation

Dianthus Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.87	/	453.407
	=	0.00

Dianthus Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.835	/	1078.555
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Dianthus Therapeutics (STU:87E) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Dianthus Therapeutics and its competitors.

Is Dianthus Therapeutics' LT-Debt-to-Total-Asset too high?

Dianthus Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Dianthus Therapeutics' LT-Debt-to-Total-Asset compare to CAI and TNGX?

Dianthus Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Dianthus Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:87E:

LT-Debt-to-Total-Asset: 0.00
GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CAI TNGX MANE CRSP ERAS ORKA TVTX CELC LEGN XENE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges DNTH:USA

Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website https://www.dianthustx.com

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

22GF Score

Get the complete analysis for STU:87E

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.00

Price

€2.53

GF Value

View STU:87E Analysis

See LT-Debt-to-Total-Asset data for all stocks →